Associated Papers
Clinical Significance of TP53-Mutant Clonal Hematopoiesis Across Diseases.
Usui Y et al.
Blood Cancer Discovery, 2025
40525786 (PubMed )
Supplement: bcd-24-0355_table_s2_suppst2.xlsx › Sheet1
Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression.
Sestokaite A et al.
International Journal of Molecular Sciences, 2023
Prevalence of Molecular Alterations in a Swiss Cohort of 512 Colorectal Carcinoma Patients by Targeted Next-Generation Sequencing Analysis in Routine Diagnostics.
Haefliger S et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology, 2023
36202073 (PubMed )
Supplement: pat-0090-0166-s01.pdf
Detecting anaplastic lymphoma kinase (ALK) gene rearrangements with next-generation sequencing remains a reliable approach in patients with non-small-cell lung cancer.
Ding Y et al.
Virchows Archiv : an International Journal of Pathology, 2022
Identification of relevant genetic alterations in cancer using topological data analysis.
Rabadán R et al.
Nature Communications, 2020
32732999 (PubMed )
Supplement: 41467_2020_17659_MOESM3_ESM.xls › TableS1
Classification of gastric cancer by EBV status combined with molecular profiling predicts patient prognosis.
He CY et al.
Clinical and Translational Medicine, 2020
32508039 (PubMed )
Supplement: CTM2-10-353-s003.xlsx › Table_S3
Non-invasive detection of EGFR and TP53 mutations through the combination of plasma, urine and sputum in advanced non-small cell lung cancer.
Wu Z et al.
Oncology Letters, 2019
31516572 (PubMed )
Supplement: Supplementary_Data.pdf
Racial Disparities in the Molecular Landscape of Cancer.
Heath EI et al.
Anticancer Research, 2018
Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.
Plagnol V et al.
Plos One, 2018
29543828 (PubMed )
Supplement: pone.0193802.s007.xlsx › Table_S7
The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer.
Coaxum SD et al.
Oncotarget, 2017
TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.
Kandioler D et al.
Ebiomedicine, 2015
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer.
Erickson BK et al.
Obstetrics and Gynecology, 2014
Select a paper to view details